NASDAQ:SWTX SpringWorks Therapeutics (SWTX) Stock Price, News & Analysis $39.52 +1.24 (+3.24%) (As of 08/21/2024 ET) Add Compare Share Share Today's Range$37.57▼$39.8850-Day Range$33.22▼$41.9152-Week Range$18.00▼$53.92Volume760,538 shsAverage Volume973,331 shsMarket Capitalization$2.93 billionP/E RatioN/ADividend YieldN/APrice Target$68.83 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get SpringWorks Therapeutics alerts: Email Address SpringWorks Therapeutics MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside74.2% Upside$68.83 Price TargetShort InterestBearish15.37% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthGrowingFrom ($3.34) to ($1.87) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.0.85 out of 5 starsMedical Sector834th out of 924 stocksBiological Products, Except Diagnostic Industry132nd out of 145 stocks 3.5 Analyst's Opinion Consensus RatingSpringWorks Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 6 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageSpringWorks Therapeutics has only been the subject of 2 research reports in the past 90 days.Read more about SpringWorks Therapeutics' stock forecast and price target. Previous Next 0.0 Short Interest Percentage of Shares Shorted15.37% of the outstanding shares of SpringWorks Therapeutics have been sold short.Short Interest Ratio / Days to CoverSpringWorks Therapeutics has a short interest ratio ("days to cover") of 13.9, which indicates bearish sentiment.Change versus previous monthShort interest in SpringWorks Therapeutics has recently increased by 7.86%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldSpringWorks Therapeutics does not currently pay a dividend.Dividend GrowthSpringWorks Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for SWTX. Previous Next 2.4 News and Social Media Coverage News SentimentSpringWorks Therapeutics has a news sentiment score of 0.29. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.44 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for SpringWorks Therapeutics this week, compared to 3 articles on an average week.Search Interest7 people have searched for SWTX on MarketBeat in the last 30 days. This is an increase of 133% compared to the previous 30 days.MarketBeat Follows3 people have added SpringWorks Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 50% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, SpringWorks Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 7.61% of the stock of SpringWorks Therapeutics is held by insiders.Read more about SpringWorks Therapeutics' insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for SpringWorks Therapeutics are expected to grow in the coming year, from ($3.34) to ($1.87) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of SpringWorks Therapeutics is -7.69, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of SpringWorks Therapeutics is -7.69, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioSpringWorks Therapeutics has a P/B Ratio of 3.95. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about SpringWorks Therapeutics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Behind the MarketsSecure this "AI Fuel" Stock Before the Billionaires Buy It AllAccording to the Washington Post, America is running out of a crucial component for AI. Without this "AI fuel," firms like NVIDIA would have to shut down their operations.Click here for the ticker >>> About SpringWorks Therapeutics Stock (NASDAQ:SWTX)SpringWorks Therapeutics, Inc., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is OGSIVEO (nirogacestat), an oral small molecule gamma secretase inhibitor that is in Phase III DeFi trial for the treatment of desmoid tumors; and Nirogacestat, is also in Phase 2 clinical development as a monotherapy for the treatment of ovarian granulosa cell tumors (GCT), a subtype of ovarian cancer. The company is also involved in the development of mirdametinib, an oral small molecule MEK inhibitor that is in Phase 2b clinical trials for the treatment of neurofibromatosis type 1-associated plexiform neurofibromas (NF1-PN); mirdametinib + lifirafenib, a combination therapy that is in Phase 1b clinical trial in patients with advanced or refractory solid tumors; and mirdametinib in monotherapy and combination approaches to treat other genetically defined solid tumors, including Phase 1/2 clinical trial for the treatment of pediatric and young adult patients with low-grade gliomas. In addition, it develops Brimarafenib (BGB-3245), an oral selective small molecule inhibitor of monomeric and dimeric forms of activating BRAF mutations. The company has collaborations with BeiGene, Ltd. and GlaxoSmithKline LLC; and license agreements with Pfizer Inc. for nirogacestat and mirdametinib. It also has a license agreement with Katholieke Universiteit Leuven and the Flanders Institute for Biotechnology for a portfolio of novel small molecule inhibitors of the TEA Domain; and Dana-Farber Cancer Institute for a portfolio of novel small molecule inhibitors of Epidermal Growth Factor Receptor. The company was founded in 2017 and is headquartered in Stamford, Connecticut.Read More SWTX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart SWTX Stock News HeadlinesAugust 16, 2024 | americanbankingnews.comIovance Biotherapeutics (NASDAQ:IOVA) and SpringWorks Therapeutics (NASDAQ:SWTX) Head-To-Head AnalysisAugust 13, 2024 | americanbankingnews.comSpringWorks Therapeutics, Inc. (NASDAQ:SWTX) Forecasted to Earn Q3 2024 Earnings of ($0.60) Per ShareAugust 22, 2024 | Porter & Company (Ad)This technology could swing the electionHidden in America's forgotten towns, a groundbreaking energy discovery is taking shape. And it's happening right in our own backyard - in the heart of Appalachia.August 9, 2024 | seekingalpha.comSpringWorks Therapeutics Recent Developments Move This To Speculative Buy (Upgrade)August 9, 2024 | finance.yahoo.comSpringWorks Therapeutics, Inc. (NASDAQ:SWTX) Just Reported Second-Quarter Earnings And Analysts Are Lifting Their EstimatesAugust 9, 2024 | markets.businessinsider.comBuy Rating Affirmed for Springworks Therapeutics on Strong Financial Results and Promising Clinical TrialsAugust 9, 2024 | markets.businessinsider.comStrong Q2 Performance and Promising Drug Pipeline Bolster Buy Rating for Springworks TherapeuticsAugust 8, 2024 | finance.yahoo.comSpringWorks Therapeutics, Inc. (NASDAQ:SWTX): Is Breakeven Near?August 22, 2024 | Porter & Company (Ad)This technology could swing the electionHidden in America's forgotten towns, a groundbreaking energy discovery is taking shape. And it's happening right in our own backyard - in the heart of Appalachia.August 7, 2024 | markets.businessinsider.comBuy Rating Affirmed for Springworks Therapeutics Amid Strong Ogsiveo Sales and Market Expansion PotentialAugust 7, 2024 | markets.businessinsider.comAnalysts Are Bullish on These Healthcare Stocks: Novo Nordisk (NVO), Springworks Therapeutics (SWTX)August 7, 2024 | seekingalpha.comSpringWorks Therapeutics, Inc. (SWTX) Q2 2024 Earnings Call TranscriptAugust 7, 2024 | seekingalpha.comSpringWorks Therapeutics, Inc. 2024 Q2 - Results - Earnings Call PresentationAugust 7, 2024 | globenewswire.comSpringWorks Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business HighlightsAugust 6, 2024 | msn.comSpringWorks Therapeutics Q2 2024 Earnings PreviewAugust 3, 2024 | benzinga.comSpringWorks Therapeutics (NASDAQ:SWTX) Stock, Short Interest ReportJuly 29, 2024 | globenewswire.comSpringWorks Therapeutics Appoints Dr. Martin Mackay to its Board of DirectorsJuly 23, 2024 | globenewswire.comSpringWorks Therapeutics to Report Second Quarter 2024 Financial Results on Wednesday, August 7, 2024See More Headlines Receive SWTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for SpringWorks Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/07/2024Today8/21/2024Next Earnings (Estimated)11/07/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:SWTX CUSIPN/A CIK1773427 Webwww.springworkstx.com Phone203-883-9490FaxN/AEmployees230Year Founded2017Price Target and Rating Average Stock Price Target$68.83 High Stock Price Target$75.00 Low Stock Price Target$52.00 Potential Upside/Downside+74.2%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)($5.14) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-325,100,000.00 Net MarginsN/A Pretax Margin-349.32% Return on Equity-56.13% Return on Assets-48.80% Debt Debt-to-Equity RatioN/A Current Ratio7.91 Quick Ratio7.77 Sales & Book Value Annual Sales$86.19 million Price / Sales33.97 Cash FlowN/A Price / Cash FlowN/A Book Value$10.01 per share Price / Book3.95Miscellaneous Outstanding Shares74,086,000Free Float68,448,000Market Cap$2.93 billion OptionableOptionable Beta0.78 Social Links Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report Key ExecutivesMr. Francis I. Perier Jr. (Age 64)M.B.A., Chief Financial Officer Comp: $768.24kDr. Badreddin Edris Ph.D. (Age 37)Chief Operating Officer Comp: $1.02MDr. James Cassidy M.D. (Age 64)Ph.D., Chief Medical Officer Comp: $904.25kMr. Michael P. Nofi (Age 53)Chief Accounting Officer Mr. Tai-An Lin Ph.D.Chief Scientific OfficerMs. Kim DiamondVice President of Communications & Investor RelationsMr. Herschel S. Weinstein J.D. (Age 67)General Counsel & Secretary Comp: $568.64kMr. Daniel J. Pichl (Age 40)Chief People Officer Comp: $428.51kMr. Bhavesh Ashar M.B.A. (Age 58)Chief Commercial Officer Comp: $729.62kMore ExecutivesKey CompetitorsBeam TherapeuticsNASDAQ:BEAMVir BiotechnologyNASDAQ:VIRChina Biologic ProductsNASDAQ:CBPOReplimune GroupNASDAQ:REPLAllogene TherapeuticsNASDAQ:ALLOView All CompetitorsInsiders & InstitutionsPerceptive Advisors LLCSold 609,500 shares on 8/16/2024Ownership: 2.226%Driehaus Capital Management LLCSold 26,993 shares on 8/16/2024Ownership: 0.103%Algert Global LLCBought 13,489 shares on 8/16/2024Ownership: 0.047%Quarry LPBought 1,800 shares on 8/16/2024Ownership: 0.007%AQR Capital Management LLCBought 18,017 shares on 8/15/2024Ownership: 0.050%View All Insider TransactionsView All Institutional Transactions SWTX Stock Analysis - Frequently Asked Questions How have SWTX shares performed this year? SpringWorks Therapeutics' stock was trading at $36.50 on January 1st, 2024. Since then, SWTX shares have increased by 8.3% and is now trading at $39.52. View the best growth stocks for 2024 here. How were SpringWorks Therapeutics' earnings last quarter? SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) announced its quarterly earnings results on Wednesday, August, 7th. The company reported ($0.54) EPS for the quarter, beating the consensus estimate of ($1.12) by $0.58. SpringWorks Therapeutics's quarterly revenue was up 59732900.0% compared to the same quarter last year. Does SpringWorks Therapeutics have any subsidiaries? The following companies are subsidiaries of SpringWorks Therapeutics: SpringWorks Subsidiary 1 Inc, SpringWorks Subsidiary 2 Inc, SpringWorks Subsidiary 3 Inc, SpringWorks Subsidiary 4 Inc, SpringWorks Therapeutics LLC, and SpringWorks Therapeutics Operating Company Inc.. When did SpringWorks Therapeutics IPO? SpringWorks Therapeutics (SWTX) raised $126 million in an initial public offering on Friday, September 13th 2019. The company issued 7,400,000 shares at $16.00-$18.00 per share. J.P. Morgan, Goldman Sachs and Cowen served as the underwriters for the IPO and Wedbush PacGrow was co-manager. Who are SpringWorks Therapeutics' major shareholders? Top institutional investors of SpringWorks Therapeutics include Maverick Capital Ltd. (3.50%), Marshall Wace LLP (3.14%), Perceptive Advisors LLC (2.23%) and Fiera Capital Corp (1.75%). Insiders that own company stock include Orbimed Advisors Llc, Daniel Pichl, Julie Hambleton, Saqib Islam and L Mary Smith. View institutional ownership trends. How do I buy shares of SpringWorks Therapeutics? Shares of SWTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of SpringWorks Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that SpringWorks Therapeutics investors own include Axsome Therapeutics (AXSM), Dicerna Pharmaceuticals (DRNA), Johnson & Johnson (JNJ), Albireo Pharma (ALBO), Gilead Sciences (GILD), Sunrun (RUN) and Alnylam Pharmaceuticals (ALNY). This page (NASDAQ:SWTX) was last updated on 8/22/2024 by MarketBeat.com Staff From Our PartnersWhat Is the $7,882 Stimulus Payment 2024?Biden’s government just announced a new government "stimulus program"... And it could hand you a payment fo...Angel Publishing | SponsoredAir Force quietly working with sub $10 stock on new techThere is a little-known energy technology stock that has made an incredible breakthrough… Which could becom...DTI | SponsoredGrab this ETF paying a huge 22% dividendImagine a world where you don't have to stress about inflation eroding your savings... Where your paycheck ...Investors Alley | SponsoredAmazon coin set to soar 25X – starting August 19thChris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredAlex's "Next Magnificent Seven" StocksToday Alex Green is releasing his new breakdown of AI's "Next Magnificent Seven." So please make some time ...The Oxford Club | Sponsored625,000% GainThe recent crypto pullback has been brutal, causing widespread panic among investors. But for us, it’s just an...Crypto Swap Profits | SponsoredThe #1 A.I. Crypto You Don’t Own (YET!)Markets are volatile right now—stocks, cryptos, you name it. But here's a crucial fact everyone is missing:...Crypto 101 Media | SponsoredYou’ve been lied to for 615 days, and countingAll of the hype around artificial intelligence has been nothing but an artificial illusion…Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding SpringWorks Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share SpringWorks Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.